dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
Published 5 years ago • 539 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
5:52
treatment of egfr nsclc after osimertinib
-
6:06
osimertinib, the standard for egfr nsclc
-
11:47
osimertinib as first-line treatment for egfr mutation-positive advanced nsclc? (bmic-017)
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
1:44
dr. oxnard on delaying second-line treatment in egfr-mutant lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
3:17
osimertinib in egfr-positive nsclc with brain metastases
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
59:36
ilcn multidisciplinary forum: understanding treatment options and resistance in egfr-positive nsclc
-
5:20
rociletinib/osimertinib for egfr t790m-negative nsclc
-
1:40
dr. piotrowska on eligibility criteria for osimertinib in lung cancer treatment
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
1:23
dr. kujtan on frontline therapy for egfr-positive nsclc